Brock, Birgitte

In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 480

One Week’s Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and α- and β-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes

Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 427

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus

Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 213

Blood-Brain Glucose Transfer in Alzheimer’s disease: Effect of GLP-1 Analog Treatment

Gejl, M., Brock, B., Egefjord, L., Vang, K., Rungby, J., & Gjedde, A. (2017) · Scientific Reports

Alzheimer's disease research and treatmentsBarrier Structure and Function Studies

Cited by 163

Capillary dysfunction is associated with symptom severity and neurodegeneration in Alzheimer's disease

Nielsen, R. B., Egefjord, L., Angleys, H., Mouridsen, K., Gejl, M., Møller, A., Brock, B., Brændgaard, H., Gottrup, H., Rungby, J., et al. (2017) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchNeurological Disease Mechanisms and Treatments

Cited by 119

Diabetic Enteropathy: From Molecule to Mechanism-Based Treatment

Meldgaard, T., Olesen, S. S., Farmer, A. D., Krogh, K., Wendel, A. A., Brock, B., Drewes, A. M., & Brock, C. (2018) · Journal of Diabetes Research

Gastrointestinal motility and disordersCongenital gastrointestinal and neural anomalies

Cited by 83

Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats

DellaValle, B., Brix, G. S., Brock, B., Gejl, M., Landau, A. M., Møller, A., Rungby, J., & Larsen, A. (2016) · Frontiers in Pharmacology

Multiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders

Cited by 39

Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double‐blind, placebo‐controlled trial

Langmach Wegeberg, A., Hansen, C. S., Farmer, A. D., Karmisholt, J. S., Drewes, A. M., Jakobsen, P. E., Brock, B., & Brock, C. (2020) · United European Gastroenterology Journal

Gastrointestinal motility and disordersDiabetes Treatment and Management

Cited by 28